Platelet aggregation indicating antigen-antibody complex formation was observed when hepatitis B surface (HB,) antigen and antibody were mixed. Platelet aggregation titers were determined for serum specimens found positive by radioimmunoassay for either HB, antigen or HB, antibody. From these determinations, incidence of HB, antigen-antibody complexes was found to be higher in HB, antigen sera than in HB, antibody sera. There was an inverse correlation between platelet aggregation titers and radioimmunoassay values that was statistically significant for HB, antigen sera but not for HB, antibody sera. The incidence of anti-complementary activity was twice as high for platelet aggregation-positive HB, antigen and antibody sera as for platelet aggregation-negative sera. HB, antigen sera that were positive by platelet aggregation exhibited nearly three times the incidence of anti-complementary activity as did HB, antibody sera. However, the low incidence of anti-complementary activity was distributed about equally between HB, antigen and antibody sera that were negative by platelet aggregation. Additional HB, antigen preincubated with HBS antigen-positive sera effectively inhibited platelet aggregation, whereas additional HB, antibody was somewhat less effective. On the other hand, preincubation of HBs antigen sera with anti-IgG serum effectively enhanced platelet aggregation, whereas preincubation of HB, antigen sera with HB, antibody did not.
let aggregation titers were determined for serum specimens found positive by radioimmunoassay for either HB, antigen or HB, antibody. From these determinations, incidence of HB, antigen-antibody complexes was found to be higher in HB, antigen sera than in HB, antibody sera. There was an inverse correlation between platelet aggregation titers and radioimmunoassay values that was statistically significant for HB, antigen sera but not for HB, antibody sera. The incidence of anti-complementary activity was twice as high for platelet aggregation-positive HB, antigen and antibody sera as for platelet aggregation-negative sera. HB, antigen sera that were positive by platelet aggregation exhibited nearly three times the incidence of anti-complementary activity as did HB, antibody sera. However, the low incidence of anti-complementary activity was distributed about equally between HB, antigen and antibody sera that were negative by platelet aggregation. Additional HB, antigen preincubated with HBS antigen-positive sera effectively inhibited platelet aggregation, whereas additional HB, antibody was somewhat less effective. On the other hand, preincubation of HBs antigen sera with anti-IgG serum effectively enhanced platelet aggregation, whereas preincubation of HB, antigen sera with HB, antibody did not.
The role of immune complexes in immunological reactions is recognized as an important factor in the immune response. Antigen complexed with antibody can interact with lymphoid cells to alter both cellular and humoral immune mechanisms in vivo. Complexes were demonstrated by Perlmann et al. (22) to inhibit antibody-dependent lymphocyte destruction of target cells bearing antigenic determinants. In addition, humoral immune responses to weakly antigenic doses of viral (10) and to nonviral (18) proteins were enhanced by homologous antibody. Formation and deposition of viral antigens in complex with antibody has been implicated in the persistence of Aleutian mink disease virus (11) , mouse leukemia virus (19) , and, more recently, hepatitis B surface (HB,) antigen in our own study (7) .
The platelet aggregation test developed by Penttinen et al. (21) has been used successfully to detect the presence of antigen-antibody complexes in serum. In this test, human platelets aggregate in the presence of antigen-antibody complexes to form a characteristic sedimentation pattern. Platelet aggregation tests have demonstrated antigen-antibody complexes in sera from patients with Mycoplasma pneumoniae infections (2), sarcoidosis (9) , varicella virus (16) , and rubella virus (17) . In post-rubella infections, the highest platelet aggregation titers coincided with clinical symptoms of thrombocytopenia purpura, which is thought to be due to deposition of viral antigen-antibody complexes. Likewise, the serum sickness and arthritic symptoms associated with HB (1) (ii) Platelet assay for complexes. Standard platelet suspension was added in 0.05-ml aliquots to each of the wells of a microtiter plate containing twofold dilutions of serum specimens diluted in Dulbecco buffer. After the reagents were mixed, microtiter plates were incubated at 4°C for 15 h and read with indirect lighting against a black background. Endpoint dilutions of specimens were determined as the maximum dilution of specimen at which a positive agglutination settling pattern was observed.
(iii) Determination of the effect of excess antigen or antibody upon platelet aggregation. In microtiter plates, specimens were diluted twofold in 0.025-ml aliquots of buffer. To one of three replicates was added 0.025 ml of diluent as control. To the second was added 0.025 ml of HBr antigen, and to the third was added 0.025 ml of HB, antibody (at the lowest dilution of antigen or antibody which gave negative platelet aggregation results when tested previously, usually a 1:4 or 1:8 dilution). After the reagents were mixed and the plates preincubated at 37°C for 2 h, 0.05 ml of the standard platelet suspension was added to each well. The plates were incubated for 15 h at 4°C, and the aggregation end points were determined.
(iv) Block titration. All dilutions were made in the wells of microtiter plates. Eleven twofold serial dilutions (1:2 through 1:2,048) of 0.025 ml of antigen were made in the horizontal rows of the plates. As a control, only diluent was added to the last vertical row. Seven twofold serial dilutions of the antibody were made in tubes with sufficient volume per tube for each of the antigen dilutions in horizontal rows. The antibody was then added to wells of each horizontal row in 0.025-ml aliquots except for the bottom horizontal row, which was used for antigen controls. Diluent (0.025 ml) was added to each well of the antigen and antibody control rows. After the reagents were mixed and the plates preincubated at 37°C for 2 h, 0.05 ml of standard platelet suspension was added to each well of the plates. The plates were further incubated at 4°C for 15 h and read for agglutination patterns.
RIA. A liquid-phase RIA was used for measuring both HB antigen and antibody (8 Table 2 show that the platelet aggregation titers were changed most by the addition of HB, antigen. Addition of excess HB, antigen to sera positive by RIA for HB, antigen caused a decreased platelet aggregation titer in 90% of the specimens. On the other hand, addition of excess HB, antigen to sera positive for HB, antibody caused alteration of the titers in only 57% of the specimens. In similar determinations, it was observed that the addition of excess HB, antibody was much less effective in altering the platelet aggregation titers.
The influence of anti-IgG upon platelet aggregation titers was also investigated. AntiIgG was preincubated with HB, antigen and HBs antibody specimens known to contain antigen-antibody complexes. We observed ( Table 3) that added anti-IgG enhanced platelet aggre- This relatively greater sensitivity of platelet aggregation to antibody concentration has been noted by Penttinen et al. (21) . It is theorized that the degree of saturation of the polyvalent antigen is the limiting factor in determining the platelet aggregation titer.
Our data indicated that sera with HB, antigen excess by RIA had a higher incidence of complexes and larger correlation ( Fig. 2) The normal sera in our test controls consistently gave low levels of agglutination (usually less than 1:8) . The positive agglutination titers for these sera, however, exhibited a normal bell-shaped frequency distribution that was evident for titers below 1:8. The greatest significance could be attached to the platelet aggregation results when agglutination titers were above 1:8. Titers less than 1:8 most likely resulted from nonspecific reactions involving agglutination of antigen-antibody systems other than HB antigen-antibody. That is, perhaps a part of the nonspecific agglutination was caused by immune complexes formed at very low concentrations by the unlimited variety of antigens with which our bodies constantly come into contact. Nevertheless, the low levels of agglutination of test sera do help contribute to the inverse correlation shown between platerlet aggregation titer and HB antigen concentration of the serum (Fig. 3) . Consequently, many of these low-titered complexes detected by platelet aggregation would be expected to con (13, 24) . Similarly, the Fc is the principal portion of the IgG molecule involved in the mechanism of complement fixation. Consequently, it is understandable that a high incidence of anti-complementary activity would be observed in sera with platelet aggregation activity (Table 1) . Anti-complementary activity in HB, sera has been shown by Schulman and Barker (23) to be reversible by the addition of excess antigen or antibody.
The platelet aggregation titers of all but one of the HB, antigen sera tested were altered by addition and preincubation of the specimen with excess antigen or antibody ( (Table 3 ). The mechanism of the enhancement has not been determined; however, rheumatoid factor is not known to affect platelet aggregation through interaction with unbound autologous globulin (24) . A likely mechanism is the reaction of anti-IgG with the IgG of the immune complex. This reaction would be facilitated by distortion of the IgG in its combination with HB, antigen, which would allow anti-IgG to react with complexes of specific (or even nonspecific) IgG bound to HB, antigen in the formation of double-antibody complexes. Several of our observations supported this explanation. HB, antigen sera had a higher incidence of immune complexes than did HB, antibody sera, and their platelet aggregation titers were more readily altered by the addition of excess HB, antigen. Finally, the incidence of anti-complementary activity was higher in HB, antigen sera than in HB, antibody sera.
